We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Gives Nod to Lilly’s Portrazza for Advanced Squamous NSCLC
FDA Gives Nod to Lilly’s Portrazza for Advanced Squamous NSCLC
Eli Lilly scored an FDA approval Tuesday for EGFR inhibitor Portrazza in combination with chemotherapy for second-line treatment in metastatic squamous non-small cell lung cancer.